RESUMO
OBJECTIVES: To analyze factors during early stage of urinary tract infection (UTI) that are associated with development of chronic UTI. METHODS: Mice were inoculated with Uropathogenic Escherichia coli (UPEC) 2 times 24 hours apart. At 1, 3, 7, 10, 14, 21 and 28 days post infection (dpi), urine bacterial loads and voiding behavior (voiding spot assay, VSA) were measured. At 1 and 28 dpi, 32 urine inflammatory cytokines/chemokines were measured using enzyme-linked immunosorbent assay (ELISA). Bladder and kidney cytokines/chemokines were measured on 28 dpi. Mice that had no more than 1 episode of urine bacterial load < 104 colony forming unit/ml during the entire 4 weeks were defined as susceptible to chronic UTI, otherwise, mice were considered resistant. RESULTS: At 28 dpi, 64.3% mice developed chronic UTI (susceptible group) and 35.7% mice did not (resistant group). Factors at 1 dpi that were predictive of chronic UTI included increased urine IL-2 (OR 11.9, 95%CI 1.1-130.8, P = .043) and increased urine IL-10 (OR 14.0, 95%CI 1.0-201.2, P = .052). At 28 dpi, there were several significant differences between the susceptible vs resistant groups including urine/tissue bacterial loads and certain urine/tissue cytokines/chemokines. CONCLUSIONS: Higher urine IL-2 and IL-10 at 1 dpi predicted chronic UTI infection in this model. There have been recent publications associating both of these cytokines to UTI susceptibility. Further explorations into IL-2 and IL-10 mediated pathways could shed light on the biology of recurrent and chronic UTI which are difficult to treat.
Assuntos
Interleucina-10/urina , Interleucina-2/urina , Infecções Urinárias/urina , Animais , Carga Bacteriana , Biomarcadores/urina , Quimiocinas/urina , Doença Crônica , Modelos Animais de Doenças , Progressão da Doença , Infecções por Escherichia coli/complicações , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Infecções Urinárias/microbiologia , Micção , Urina/microbiologiaRESUMO
BACKGROUND: Predictive factors for the rate of decline in kidney allograft function beyond the first post-transplant year have not been thoroughly studied. We aimed to determine whether a single measurement of serum and urinary interleukin 2, interleukin 8 and interleukin 10 at 1-15 years after kidney transplantation could predict a decline in estimated glomerular filtration rate (eGFR) over a 2-year period. RESULTS: Greater serum concentrations of interleukin 8 and interleukin 10 in 30 recipients of kidney allograft at enrollment were associated with lower eGFR after 1 year (beta = - 0.616, p = 0.002 and beta = - 0.393, p = 0.035, respectively), whereas serum concentrations of interleukin 8 also demonstrated significant association with eGFR after 2 years of follow-up (beta = - 0.594, p = 0.003). Higher urinary interleukin 2 concentrations were associated with lower eGFR at baseline (rho = - 0.368, p = 0.049) and after the first (beta = - 0.481, p = 0.008) and the second year (beta = - 0.502, p = 0.006) of follow-up. Higher urinary interleukin 2 concentrations predicted certain decline in eGFR of ≥ 25% from baseline after 1 year of follow-up in logistic regression: odds ratio = 2.94, confidence interval 1.06-8.18, p = 0.038. When combined with time after transplantation, urinary interleukin 2 demonstrated good accuracy in predicting rapid decline in eGFR by > -5 mL/min/1.73 m2/year (area under the receiver-operator characteristic curve: 0.855, confidence interval 0.687-1.000, and p = 0.008). CONCLUSIONS: Our findings suggest that urinary interleukin 2 in the late period after kidney transplantation has promise in identifying patients who are at risk for progressive loss of graft function in a short-time perspective and need closer monitoring.
Assuntos
Interleucina-2/urina , Transplante de Rim , Complicações Pós-Operatórias/urina , Adolescente , Adulto , Aloenxertos , Feminino , Seguimentos , Taxa de Filtração Glomerular , Sobrevivência de Enxerto , Humanos , Interleucina-10/sangue , Interleucina-10/urina , Interleucina-2/sangue , Interleucina-8/sangue , Interleucina-8/urina , Rim/fisiopatologia , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/sangue , Fatores de Risco , Adulto JovemRESUMO
BACKGROUND: Glomerulonephritides (GNs) represent common causes of chronic kidney disease associated with a wide spectrum of clinical and histological features. Various factors that activate the inflammatory cascade are involved in the development of kidney injury. The aim of this study was to estimate the urinary excretion of pro-inflammatory (IL-2, INF-γ, TNF-α, IL-6, IL-17) and anti-inflammatory (IL-4, IL-10, TGF-ß1) cytokines, as well as the chemokine MCP-1 in patients with various types of GN treated by immunosuppressive drugs and to identify any prognostic value of excreted cytokines for future renal function. PATIENTS AND METHODS: Ninety-seven patients (62 M/35 F, age 53.1 ± 15.6 years) with primary glomerulonephritis and 32 healthy controls were studied. The original diagnoses were membranous nephropathy (MN, n=36), IgA nephropathy (IgAN, n=31) and minimal changes disease or focal segmental glomerulosclerosis (MCD/FSGS, n=30). All patients had been treated with immunosuppressive drugs and, at the time of measurement of urinary cytokine excretion, were either in clinical remission or still had active disease with persistent proteinuria. RESULTS: GN patients had significantly higher levels of all cytokines and MCP-1 compared to healthy controls. A strong positive correlation between TGF-ß1 and MCP-1 concentrations was observed in all GN patients. Increased urinary excretion of all tested cytokines apart from TNF-α and TGF-ß1 was observed even in patients with clinical remission. The main difference between patients with proteinuria and those in clinical remission was the level of MCP-1 urinary excretion. The urinary excretion of MCP-1 and TGF-ß1 was significantly higher in patients with MN who showed deterioration of renal function over a follow-up period of five years. CONCLUSIONS: Increased levels of cytokines are observed in the urine of patients with different types of glomerulonephritis, even after the achievement of clinical remission with the administration of immunosuppressive drugs. Urinary excretion of MCP-1 and TGF-ß1 indicates the ongoing inflammatory and fibrotic processes in the kidney and is probably related to unfavourable outcomes.
Assuntos
Citocinas/urina , Glomerulonefrite/tratamento farmacológico , Glomerulonefrite/imunologia , Imunossupressores/uso terapêutico , Rim/fisiopatologia , Adulto , Idoso , Quimiocina CCL2/urina , Feminino , Glomerulonefrite/fisiopatologia , Glomerulosclerose Segmentar e Focal/tratamento farmacológico , Glomerulosclerose Segmentar e Focal/imunologia , Humanos , Interferon gama/urina , Interleucina-10/urina , Interleucina-17/urina , Interleucina-2/urina , Interleucina-4/urina , Interleucina-6/urina , Masculino , Pessoa de Meia-Idade , Prognóstico , ProteinúriaRESUMO
BACKGROUND: Inflammation is implicated in many adverse health conditions, and recent interest has focused on the effects of chronic low-grade inflammation in generally healthy populations. Cytokines measured in plasma or serum are commonly used as biomarkers of systemic levels of inflammation. Measurement of cytokines in urine may offer a simpler and less invasive alternative, although the degree to which levels of cytokines correlate in plasma and urine among healthy individuals is unknown. MATERIALS AND METHODS: We assessed the correlation of blood and urine levels of 13 cytokines, including interleukin (IL)-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70) and IL-13, granulocyte macrophage colony-stimulating factor, interferon gamma and tumour necrosis factor alpha in 61 healthy women aged 18-30. Cytokine concentrations were considered with and without correction for creatinine. RESULTS: Plasma and urine levels of the 13 cytokines were not significantly correlated using measured urinary cytokine concentrations and after adjustment for creatinine. Correlation coefficients for log-transformed cytokine concentrations in paired plasma and urine specimens ranged from -0.28 to 0.087. CONCLUSIONS: These results suggest that urine has limited utility as a proxy for plasma for the measurement of inflammatory factors in a healthy population with low levels of inflammation.
Assuntos
Citocinas/sangue , Citocinas/urina , Adolescente , Adulto , Biomarcadores/sangue , Biomarcadores/urina , Creatinina/sangue , Creatinina/urina , Feminino , Fator Estimulador de Colônias de Granulócitos e Macrófagos/sangue , Fator Estimulador de Colônias de Granulócitos e Macrófagos/urina , Humanos , Inflamação , Interferon gama/sangue , Interferon gama/urina , Interleucina-10/sangue , Interleucina-10/urina , Interleucina-12/sangue , Interleucina-12/urina , Interleucina-13/sangue , Interleucina-13/urina , Interleucina-1beta/sangue , Interleucina-1beta/urina , Interleucina-2/sangue , Interleucina-2/urina , Interleucina-4/sangue , Interleucina-4/urina , Interleucina-5/sangue , Interleucina-5/urina , Interleucina-6/sangue , Interleucina-6/urina , Interleucina-7/sangue , Interleucina-7/urina , Interleucina-8/sangue , Interleucina-8/urina , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/urina , Adulto JovemRESUMO
The study was organized to provide additional characteristic of chronic dysfunction of renal allo-transplant using such biomarkers of serum and urine as enzymes (alanine aminotransferase), aspartate aminotransferase, gamma- glutamiltransferase, alkaline phosphatase, N-acetyl-ß-D-glucosaminidase, interleukins (IL-2, IL-8, IL-10), beta-2- microglobulin. The chronic dysfunction of renal allo-transplant is characterized by increasing of concentration of IL-10 and beta-2-microglobulin in serum and increasing of concentration of beta-2-microglobulin, IL-2, IL-8 in urine and increasing of activity of N-acetyl-ß-D-glucosaminidase, alkaline phosphatase, aspartate aminotransferase, gamma-glutamiltransferase as compared with patients with satisfactory function of renal allo-transplant. The multivariant logistic regression analysis established that only activity of N-acetyl-ß-D-glucosaminidase in urine was reliably independently related to chronic dysfunction of renal allo-transplant. It is assumed that increasing of concentration of beta-2-microglobulin in serum testifies glomerular dysfunction and in urine--tubular dysfunction of renal allo-transplant. The enzymeuria indicates continuing damage of epithelium of proximal tubules of nephron. The classification of patients with satisfactory function and chronic dysfunction of renal allo-transplant established that the highest indicators of square under ROC-curves had concentration of beta-2-microglobulin in serum (0.858 ± 0.061) and urine (0.733 ± 0.079) and activity of N-acetyl-ß-D-glucosaminidase in urine (0.701 ± 0.061). To specify diagnosis of chronic dysfunction of renal allo-transplant the most useful (ratio of likelihood of positive result 10 and 11 correspondingly) are tests of beta-2- microglobulin in serum (more than 8.55 mkg/ml) and N-acetyl-ß-D-glucosaminidase/creatinine in urine (more than 34 nmol/(sl)/ mmol/l). These discoveries require further validation and confirmation by implementation of morphological analysis of bioptat of renal allo-transplant.
Assuntos
Acetilglucosaminidase/urina , Interleucina-10/sangue , Interleucina-2/urina , Interleucina-8/urina , Transplante de Rim , Insuficiência Renal Crônica/diagnóstico , Microglobulina beta-2 , Acetilglucosaminidase/sangue , Adolescente , Adulto , Alanina Transaminase/sangue , Alanina Transaminase/urina , Fosfatase Alcalina/sangue , Fosfatase Alcalina/urina , Aspartato Aminotransferases/sangue , Aspartato Aminotransferases/urina , Biomarcadores/sangue , Biomarcadores/urina , Humanos , Interleucina-10/urina , Interleucina-2/sangue , Interleucina-8/sangue , Rim/metabolismo , Rim/patologia , Masculino , Pessoa de Meia-Idade , Curva ROC , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/patologia , Insuficiência Renal Crônica/urina , Estudos Retrospectivos , Transplante Homólogo , Microglobulina beta-2/sangue , Microglobulina beta-2/urina , gama-Glutamiltransferase/sangue , gama-Glutamiltransferase/urinaRESUMO
Bladder cancer (BCA) is one of the most common cancers. In 2010 in Poland, 6296 people developed bladder cancer and 3110 people died of it. Immunotherapy with BCG (Bacillus Calmette-Guérin) is by far the most effective adjuvant therapy. Noninfiltrating muscle membrane changes, that is, stages Ta, Tis and T1 qualify for BCG immunotherapy. BCG immunotherapy comprises series of bladder instillations, containing attenuated strain of Mycobacterium bovis. The effectiveness of immunotherapy in non-invasive bladder cancer is 70% 5-year survival without recurrence of the tumor. The treatment leads to a reduction of the residual tumor mass, but also to the delay and/or prevention of relapse, disease progression and ultimately death. Cytokines, as key mediators of immune response, play an important role in the pathogenesis of bladder cancer, which occurrence is stimulated by the inflammatory process. BCG immunotherapy provokes an intensive immunological response by the increase of cytokine production. Genetic variants determine inter-individual differences in the incidence of this cancer, as well as the response to the therapy. This is evidenced by the presence of differences in genetic variants of cytokines correlated with the varied risk of bladder cancer incidence. It is believed that concentrations of particular cytokines in urine after installation of BCG may indicate response to the therapy. Increased levels of Th1 cytokines - IFN-γ, IL-2 and TNF-α are correlated with longer survival time without recurrence, whereas high levels of Th2 cytokines such as IL-10, predict unsuccessful BCG therapy.
Assuntos
Vacina BCG/uso terapêutico , Biomarcadores Tumorais/urina , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/urina , Administração Intravesical , Antineoplásicos/uso terapêutico , Vacina BCG/imunologia , Citocinas/biossíntese , Humanos , Imunoterapia , Interleucina-10/urina , Interleucina-2/urina , Recidiva Local de Neoplasia/prevenção & controle , Taxa de Sobrevida , Resultado do Tratamento , Fator de Necrose Tumoral alfa/urina , Neoplasias da Bexiga Urinária/imunologia , Neoplasias da Bexiga Urinária/mortalidadeRESUMO
OBJECTIVE: In search of potential urinary biomarkers of obstructive nephropathy, this study examined whether a potential change in the concentration of urinary cytokines [interferon-γ(IFN-γ), interleukin-1ß (IL-1ß), IL-2, IL-6, IL-10 and tumour necrosis factor-α (TNF-α)] reliably reflects changes in renal parenchymal levels of the same cytokines following the release of acute and chronic unilateral ureteral obstruction, respectively. MATERIAL AND METHODS: Acute obstruction was performed in 12 adult rats. After 48 h, six rats were used for selective urine collection and six rats had their kidneys removed and dissected into inner medulla and cortex. Chronic obstruction was performed in newborn rats. After 10 weeks, a similar set-up to that of the acute study was implemented. Sham-operated rats were prepared in parallel. Urine and tissue cytokines were measured with a bead-based multiplex sandwich immunoassay and analysed on a Luminex 100 IS instrument. RESULTS: In the acute study, there were significantly increased concentrations of IL-1ß and IL-6 in inner medulla and in urine from the obstructed kidney, significantly increased concentrations of TNF-α in urine from the obstructed kidney and, importantly, significantly increased levels of IL-10 in cortex and in urine from the non-obstructed kidney. In the chronic study, there were similar changes in IL-1ß and IL-6 (not significant) but no changes in TNF-α and IL-10. CONCLUSIONS: This study showed that inflammatory cytokines can be detected both in renal parenchyma and in urine from rats with experimental unilateral ureteral obstruction. Further studies are needed to confirm the diagnostic accuracy of IL-1ß, IL-6, IL-10 and TNF-α in urine.
Assuntos
Citocinas/urina , Hidronefrose/urina , Rim/metabolismo , Obstrução Ureteral/urina , Doença Aguda , Animais , Biomarcadores/urina , Doença Crônica , Citocinas/metabolismo , Hidronefrose/etiologia , Hidronefrose/metabolismo , Interferon gama/urina , Interleucina-1beta/urina , Interleucina-2/urina , Interleucina-6/urina , Masculino , Ratos , Ratos Wistar , Estatísticas não Paramétricas , Fator de Necrose Tumoral alfa/urina , Obstrução Ureteral/complicações , Obstrução Ureteral/metabolismoRESUMO
OBJECTIVE: Acute glycemic variability contributes to diabetic complications potentially through induction of inflammation. Our objective was to determine whether acute hyperglycemia affects urinary secretion of inflammatory cytokines/chemokines in humans with uncomplicated type 1 diabetes. RESEARCH DESIGN AND METHODS: Blood pressure, renal hemodynamics (inulin and paraaminohippurate clearances), and urine samples were obtained after 6 h of clamped euglycemia (4-6 mmol/l) and hyperglycemia (9-11 mmol/l) on two consecutive days in subjects with type 1 diabetes (n = 25). Forty-two urinary cytokines/chemokines were measured using a Luminex platform. RESULTS: Clamped hyperglycemia produced an expected increase in glomerular filtration rate (131 ± 4 to 148 ± 8 ml/min/1.73 m²). Clamped hyperglycemia was associated with significant increases in urinary eotaxin, fibroblast growth factor-2, granulocyte-macrophage colony-stimulating factor, interferon-α 2, interleukin-2 and -12, monocyte chemoattractant protein-3, macrophage-derived chemokine, macrophage inflammatory protein-1α, platelet-derived growth factor, tumor necrosis factor-α, and CD40 ligand (P < 0.05). CONCLUSIONS: Acute hyperglycemia results in increased urinary excretion of inflammatory cytokines/chemokines in humans with uncomplicated type 1 diabetes, and this may contribute to kidney injury.
Assuntos
Quimiocinas/urina , Citocinas/urina , Diabetes Mellitus Tipo 1/urina , Hiperglicemia/urina , Adolescente , Adulto , Quimiocina CCL7/urina , Feminino , Taxa de Filtração Glomerular , Humanos , Interferon-alfa/urina , Interleucina-2/urina , Masculino , Fator de Crescimento Derivado de Plaquetas/urina , Fator de Necrose Tumoral alfa/urina , Adulto JovemRESUMO
AIMS: Potent immunosuppressive effect of tacrolimus has encouraged its topical application for achieving local anti-inflammatory effect. However, its poor aqueous solubility presents challenges in formulating biocompatible instillations to justify the investigation of liposomes as vehicle for tacrolimus. METHODS: Adult female Sprague-Dawley rats (N=52) divided into 4 groups were injected with cyclophosphamide (CYP) (200 mg/kg, ip) except for sham (saline injection, ip). Other three groups were instilled with either saline (1 cc, retained for 1 hr), liposome (LP- 1 cc) or liposomal encapsulated tacrolimus (LFK- 0.2 mg tacrolimus/1 ml LP). Baseline cystometrogram was performed on day 1 and day 3 prior to bladder harvest for histological staining (N=24) in all groups except sham. In addition, 4-hr baseline urine on day 1 and day 3 was collected from all groups for urine PGE2 assay and bladder harvested for PGE2 and IL2 assay on day 3 (N=28). RESULTS: Rats treated with LFK demonstrated suppression of CYP induced inflammatory reaction with reduced EP4 staining and bladder overactivity (intercontraction interval 61.0% decrease in untreated animals) as well as normalized the several fold elevation of IL 2 and PGE2 levels in tissue and urine. CYP induced effects were not suppressed in rats left untreated with tacrolimus. CONCLUSIONS: This is the first report of immunosuppression in bladder by intravesical delivery of tacrolimus using liposomes. LFK significantly inhibited CYP induced inflammatory cystitis through the modulation of IL2, PGE2, and EP4 function. These findings support investigation of local tacrolimus in cases of inflammatory cystitis refractory to conventional therapy.
Assuntos
Cistite/prevenção & controle , Imunossupressores/administração & dosagem , Tacrolimo/administração & dosagem , Bexiga Urinária/efeitos dos fármacos , Administração Intravesical , Animais , Ciclofosfamida , Cistite/induzido quimicamente , Cistite/metabolismo , Cistite/fisiopatologia , Dinoprostona/metabolismo , Dinoprostona/urina , Modelos Animais de Doenças , Feminino , Imunossupressores/sangue , Interleucina-2/metabolismo , Interleucina-2/urina , Lipossomos , Ratos , Ratos Sprague-Dawley , Receptores de Prostaglandina E Subtipo EP4/metabolismo , Tacrolimo/sangue , Fatores de Tempo , Bexiga Urinária/metabolismo , Bexiga Urinária/fisiopatologia , Micção/efeitos dos fármacosRESUMO
One recent line of cancer research shows increasing interest for biological factor such as IL-2, TNF-alpha, and leptin, which have been found to participate in the development and progression of non-small cell lung cancer (NSCLC). The aim of this study was to measure IL-2, TNF-alpha, and leptin concentrations in the airways and in the systemic circle of patients with NSCLC, investigating the role of these factors in the lung tumors. We enrolled 32 patients (17 men, 71 +/- 7 years) with a histological diagnosis of NSCLC and 20 healthy ex-smoker controls, negative for computed tomography of the chest (14 men, 69 +/- 8 years). IL-2, TNF-alpha, and leptin levels were measured in the serum, the urine, the bronchoalveolar lavage, the induced sputum, and exhaled breath condensate (EBC) of patients enrolled by means of a specific enzyme immunoassay kit. Higher concentrations of IL-2, TNF-alpha and leptin were found in NSCLC patients than in controls (p < 0.0001). A statistically significant increase of IL-2, TNF-alpha, and leptin concentrations was observed in patients from stage I to stage III of NSCLC. These findings suggest that IL-2, TNF-alpha, and the leptin play an important role in the cancerogenesis of NSCLC. Their measure in the EBC could be proposed as noninvasive markers for an early detection of NSCLC and in the follow-up of this tumor.
Assuntos
Líquido da Lavagem Broncoalveolar/química , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Interleucina-2/análise , Leptina/análise , Neoplasias Pulmonares/metabolismo , Escarro/química , Fator de Necrose Tumoral alfa/análise , Idoso , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/urina , Biópsia por Agulha Fina , Testes Respiratórios , Broncoscopia , Carcinoma Pulmonar de Células não Pequenas/diagnóstico , Carcinoma Pulmonar de Células não Pequenas/patologia , Diagnóstico Precoce , Feminino , Humanos , Interleucina-2/sangue , Interleucina-2/urina , Leptina/sangue , Leptina/urina , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/urinaRESUMO
BACKGROUND & OBJECTIVES: In spite of potent immunosuppression, acute rejection continues to be the single largest cause of graft dysfunction after renal transplantation. Renal allograft biopsy, though invasive, continues to be the reference standard, though certain clinical and biochemical parameters are helpful in assessment of these patients. Acute renal allograft rejection is mediated by T lymphocytes, which express increased number of interleukin-2 receptors (IL-2R). The soluble component of IL-2R in serum and urine may be useful in detecting early graft rejection. This study assesses the possibility of using serum and urinary IL-2R estimation in early prediction and diagnosis of acute renal allograft rejection. METHODS: Sequential estimation of serum and urinary IL-2R levels along with serum creatinine values were assessed in 23 live related renal allograft recipients. The age of renal allograft recipients was 35+/-8.3 yr, with male:female ratio of 22:1. Samples were collected pre-transplant (day 0) and post-transplant upto 30 days and the patients were followed for 6 months after transplantation. Eight recipients experienced graft dysfunction and graft biopsies were evaluated. RESULTS: Serum and urinary IL-2R patterns along with serum creatinine levels were correlated with the occurrence of graft rejection on histology. Eight recipients experienced acute graft rejection after transplantation and 15 had stable graft function. Serum IL-2R levels at various periods after transplantation were found to be significantly (P<0.05) elevated in graft recipients experiencing acute rejection as compared to the non-rejection group. The rise in urinary IL-2R levels in some of the rejection group recipients, was not statistically significant. INTERPRETATION & CONCLUSION: Sequential serum and urinary IL-2R assay may serve as a predicter for early graft dysfunction. Study with larger sample size and for longer duration is required to further validate the results.
Assuntos
Rejeição de Enxerto , Interleucina-2/sangue , Interleucina-2/urina , Transplante de Rim , Adolescente , Adulto , Creatinina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Receptores de Interleucina-2/biossíntese , Linfócitos T/metabolismo , Fatores de Tempo , TransplanteRESUMO
We evaluated the clinical significance of Th1(IL-2)/Th2(IL-10) urinary profiles during a weekly induction course lasting 6 weeks, followed by a weekly maintenance therapy schedule for 3 weeks. Urinary IL-2 and /IL-10 were measured by ELISA in 39 patients receiving BCG for superficial bladder cancer or carcinoma in situ. Measurements were made after each instillation of 81 mg of BCG Connaught (Immucyst) during the induction course and the 3-week maintenance therapy (given at 3, 6, 12, 18, 24, 30 and 36 months). Cytokine levels were correlated with the risk of recurrence, progression, leukocyturia and adverse events. Median follow-up was 35 months (range 7-72 months). Complete responses to BCG were obtained in 30 patients (77%); the remaining 9 patients relapsed (23%), and 4 of these patients progressed (10.2%). Failure to detect urinary IL-2 during BCG induction course and the first extended induction cycle (6+3 schedule) correlated with time to recurrence (p = 0.01) and progression (p = 0.01). During the extended induction cycle, the first instillation was associated with an IL-2 cytokine profile, whereas the second and third instillations were associated with a switch to an IL-10 cytokine profile. This switch was associated with leukocyturia (p = 0.0001) and adverse events (p = 0.03). The 6+3 schedule is associated with urinary IL-2 overproduction and improved recurrence- and progression-free survival. During the BCG extended induction cycle, the favorable IL-2 urinary cytokine pattern gradually switches to an IL-10 profile, suggesting that the schedule based on 3 weekly instillations may be unsuitable for some patients and that the dose and frequency of maintenance BCG instillations may be adapted to individual urinary cytokine levels.
Assuntos
Vacina BCG/uso terapêutico , Interleucina-2/urina , Neoplasias da Bexiga Urinária/terapia , Administração Intravesical , Idoso , Idoso de 80 Anos ou mais , Vacina BCG/administração & dosagem , Feminino , Humanos , Interleucina-10/urina , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Neoplasias da Bexiga Urinária/imunologiaRESUMO
PURPOSE: The mechanism by which bacillus Calmette-Guérin (BCG) mediates antitumor activity has not been clearly established. Specific cytokines in the urine after BCG intravesical instillation therapy may serve as a prognostic factor of treatment response. In this study, various urinary cytokines such as interleukin-1beta (IL-1beta), IL-2, IL-6, IL-8. IL-10, IL-12, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) were measured. MATERIALS AND METHODS: In total 20 patients were treated with BCG intravesical instillation therapy for carcinoma in situ of the bladder. At the completion of the first and eighth instillations, spontaneously voided urine specimens were collected before BCG instillation, every 2 h until 12 h, and thereafter until 24 h. All specimens were ultrafiltrated using an ADVANTEC UK-10 membrane. The cytokines were measured using ELISA and RIA techniques. RESULTS: Significantly higher levels of IL-2, IL-6, IL-8, IL-10, IFN-gamma, and TNF-alpha were detected in the eighth instillation as compared to the first instillation ( p<0.001). After BCG intravesical instillation therapy, treatment failure occurred in 6 of the 20 patients (30%), including primary failure (persistence of CIS) in 3, and de novo failure (tumor recurrence) in 3 with a median follow-up of 46.9 months. Significantly higher production of IL-2, IL-6, IL-8, IL-10, and TNF-alpha was observed in the responder group than in the non-responder group ( p<0.05). Multivariate analysis revealed IL-2 as an independent prognostic cytokine of responder status. CONCLUSIONS: This study indicates that urinary IL-2 at the eighth instillation of BCG may serve as a valuable prognostic factor of treatment efficacy as well as tumor recurrence after treatment.
Assuntos
Vacina BCG/uso terapêutico , Carcinoma in Situ/tratamento farmacológico , Imunoterapia , Interleucina-2/urina , Fator de Necrose Tumoral alfa/urina , Neoplasias da Bexiga Urinária/tratamento farmacológico , Administração Intravesical , Idoso , Idoso de 80 Anos ou mais , Vacina BCG/administração & dosagem , Biomarcadores Tumorais/urina , Carcinoma in Situ/urina , Estudos de Casos e Controles , Citocinas/urina , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/imunologia , Recidiva Local de Neoplasia/terapia , Recidiva Local de Neoplasia/urina , Estadiamento de Neoplasias , Prognóstico , Neoplasias da Bexiga Urinária/urinaRESUMO
PURPOSE: Interleukin (IL)-2 and interferon-gamma are released during T helper 1 lymphocyte responses, while IL-10 is released during T helper 2 responses. We evaluated the prognostic value of urinary IL-2, interferon-gamma and IL-10 levels in patients with superficial bladder cancer treated with bacillus Calmette-Guerin (BCG) instillation. METHODS: Urinary IL-2, interferon-gamma and IL-10 were measured by enzyme-linked immunosorbent assay in 37 patients receiving BCG for stages Ta/T1 superficial bladder cancer, and carcinoma in situ. Measurements were made after instillations 5 and 6 during a course of 6 weekly instillations of 150 mg. BCG, Pasteur strain. Correlations of cytokine levels with the clinical outcome were evaluated using the log rank test. RESULTS: Median followup was 29 months. Patients with urinary IL-2 less than 27 pg./micromol. creatinine were significantly more likely to have recurrences than those with higher values (log rank test p = 0.0009). Urinary IL-10 and interferon-gamma levels had no apparent impact on the risk of recurrence or progression. CONCLUSION: Urinary IL-2 levels may serve to identify patients at risk for bladder cancer recurrence after a single course of BCG and, thus, to tailor individual treatment.
Assuntos
Vacina BCG/uso terapêutico , Carcinoma de Células de Transição/tratamento farmacológico , Interferon gama/urina , Interleucina-2/urina , Neoplasias da Bexiga Urinária/tratamento farmacológico , Idoso , Vacina BCG/administração & dosagem , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Interleucina-10/urina , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Prognóstico , Linfócitos T Auxiliares-Indutores/metabolismoRESUMO
PURPOSE: Interleukin (IL)-2 and interferon-gamma are released during T helper 1 lymphocyte responses and IL-10 is released during T helper 2 lymphocyte responses. We have previously reported that a T helper 1 lymphocyte urinary cytokine profile is associated with a favorable prognosis after bacillus Calmette-Guerin (BCG) treatment. We evaluated the T helper 1/2 lymphocyte cytokine profiles during courses 1 and 2 of 6 weekly BCG instillations. MATERIALS AND METHODS: Urinary interferon-gamma, IL-2 and IL-10 were measured by enzyme-linked immunosorbent assay after each of 6 weekly instillations of 150 mg. BCG, Pasteur strain, in 19 patients with superficial stages Ta and T1 bladder cancer, and carcinoma in situ. The 11 patients who did not respond to course 1 were re-treated according to the same schedule and reevaluated. RESULTS: During course 1 interferon-gamma was higher than during course 2 (p <0.001), which was associated with nonrecurrence (p <0.001). In contrast, IL-2 cytokine was higher after course 2 (p <0.01), which was associated with a BCG response (p = 0.01). Interferon-gamma and IL-10 correlated during courses 1 and 2 (p = 0.04 and 0.0004, respectively). We distinguished groups 1-immediate T helper 1 lymphocyte profile consisting of responders to course 1 with high interferon-gamma, IL-2 and IL-10, 2-delayed T helper 1 lymphocyte profile consisting of responders to course 2 with early high IL-2 and 3-consisting of nonresponders to the 2 courses with low interferon-gamma, IL-2 and IL-10. CONCLUSIONS: A T helper 1 lymphocyte urinary cytokine profile was associated with a clinical response to BCG. A repeat BCG course induces a favorable immune response in a subset of patients, suggesting that maintenance therapy may be beneficial.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Vacina BCG/administração & dosagem , Carcinoma de Células de Transição/tratamento farmacológico , Carcinoma de Células de Transição/urina , Interferon gama/urina , Interleucina-10/urina , Interleucina-2/urina , Linfócitos T Auxiliares-Indutores/imunologia , Neoplasias da Bexiga Urinária/tratamento farmacológico , Neoplasias da Bexiga Urinária/urina , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Falha de TratamentoRESUMO
BACKGROUND: We evaluated the potential role of serial preinstillation levels of several interleukins, TNFalpha and urinary tumor markers to monitor patients with bladder cancer receiving intravesical BCG. PATIENTS AND METHODS: 121 urine samples were collected from: patients with bladder cancer treated with BCG (group 1); patients with bladder cancer receiving other intravesical treatment (group 2) and patients with urinary tract infections (group 3). Cytokines [IL-2, IL6 and [L8] and TNFalpha and urinary tumor markers [UBC, CYFRA 21-1 and NMP22] were measured by immunoassays. RESULTS: In 3 out of 15 BCG non-responders that recurred over the period of the study, no cytokine peak for IL-2, IL-6 or TNFa were detected. Urinary tumor markers increased in 2 out of 3 of these patients earlier than scheduled cystoscopies. Cytokine measurement was heterogeneous among 12 out of 15 BCG-responding patients: there were low levels of IL-6 and TNFalpha and peaks of IL-2 and IL-8 in 10 out of 12 and 4 out of 12 patients, respectively. During responding patients' follow-up we observed false-positive results in 7 out of 65 urine samples for UBC, 8 out of 65 for CYFRA 21-1 and 20 out of 65 for NMP22. Urinary tract infections were the main factor associated with non-specific elevations of IL-6 and IL-8 and urinary tumor markers in all groups of patients. CONCLUSION: Although larger series are required to confirn our preliminary observations, our data argue for a potential predictive role for IL-2 of favourable response to BCG therapy. Monitoring BCG with urinary tumor markers could early detect recurrence in non-responding patients.
Assuntos
Antígenos de Neoplasias/urina , Vacina BCG/uso terapêutico , Biomarcadores Tumorais/urina , Carcinoma de Células de Transição/urina , Citocinas/urina , Imunoterapia , Proteínas de Neoplasias/urina , Neoplasias da Bexiga Urinária/urina , Administração Intravesical , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células de Transição/tratamento farmacológico , Carcinoma de Células de Transição/mortalidade , Carcinoma de Células de Transição/terapia , Quimioterapia Adjuvante , Terapia Combinada , Progressão da Doença , Humanos , Interleucina-2/urina , Interleucina-6/urina , Interleucina-8/urina , Queratina-19 , Queratinas , Mitomicina/administração & dosagem , Proteínas Nucleares/urina , Tiotepa/administração & dosagem , Resultado do Tratamento , Fator de Necrose Tumoral alfa/urina , Neoplasias da Bexiga Urinária/mortalidade , Neoplasias da Bexiga Urinária/terapiaRESUMO
BACKGROUND: Acute rejection and urinary tract infection (UTI) both increase nitric oxide synthase (NOS) activity in urine from renal transplant patients. Also, with rejection, a regulatory interplay between nitric oxide (NO) and cytokines has been suggested. Thus, measurement of the temporal changes of NOS products and cytokines in urine will provide a strategy for the diagnosis of acute rejection and for its differentiation from UTI. METHODS: Soluble interleukins (ILs) and NOS-related products, cyclic GMP (cGMP), nitrate, and nitrite were measured in 192 urine samples consecutively collected from 13 patients within the first three months of transplantation. Sixty-seven additional urine specimens were collected randomly from 24 patients for follow-up analysis of the nitrate test. RESULTS: Among patients who experienced rejection, the percentage (%) binding of IL-2 increased within the first five days (P = 0.0004) after transplantation and one to five days prior to the clinical diagnosis (dx) of rejection (P = 0.02). Tumor necrosis factor-alpha, IL-6, and IL-8 increased at the time of rejection dx (P < or = 0.01). With UTI, IL-2 (P = 0.01) decreased one to five days prior to dx, and IL-10 (P = 0.003) increased one to five days after dx. Although cGMP and nitrate are dependent variables, cGMP increased (P < or =0.0009) with both rejection and UTI, and nitrate increased (P = 0.0001) with rejection and decreased (P = 0.0001) with UTI. Prior to formal dx (1 to 5 days), urine nitrate clearly differentiated rejection (3004 to 7451 micromol/L) from UTI (90 to 885 micromol/L) and controls (1059 to 3235 micromol/L). The additional 67 urines demonstrated that the sensitivity of the nitrate test for rejection and UTI was 100%. CONCLUSIONS: In renal transplant patients, specific temporal changes in urine cytokine levels do occur with acute rejection and UTI, but urine nitrate levels are the most precise at differentiating rejection from UTI.
Assuntos
Citocinas/urina , Rejeição de Enxerto/urina , Falência Renal Crônica/cirurgia , Transplante de Rim , Óxido Nítrico/urina , Doença Aguda , Adulto , Creatinina/sangue , Creatinina/urina , GMP Cíclico/urina , Feminino , Seguimentos , Rejeição de Enxerto/imunologia , Rejeição de Enxerto/microbiologia , Humanos , Interleucina-10/urina , Interleucina-2/urina , Interleucina-6/urina , Interleucina-8/urina , Falência Renal Crônica/imunologia , Falência Renal Crônica/urina , Masculino , Pessoa de Meia-Idade , Nitratos/urina , Nitritos/urina , Valor Preditivo dos Testes , Fatores de Tempo , Fator de Necrose Tumoral alfa/urina , Infecções Urinárias/imunologia , Infecções Urinárias/urinaRESUMO
PATIENTS AND METHODS: We studied five biological fluids which were easily accessible to immunological examination (cerebrospinal fluid, plasma, tears, saliva and urine) in 25 patients with multiple sclerosis, clinically definite according to the criteria of Cleveland, Ohio (1991) and tabulated according to the Kurztke's expanded disability status scale. The samples were obtained simultaneously during a clinical bout of the disease before any pharmacological or immunosuppressive treatment had been given. RESULTS: The soluble interleukin-2 levels were significantly raised in at least three of these fluids--always absent from the urine--when compared with normal controls. The sensitivity and specificity of this determination for diagnosis of the condition was greater than that of other immunochemical parameters--oligoclonal distribution of immunoglobulins (specifically of IgG), imbalance of the light Kappa and Lambda chains--and physiological studies (evoked potentials). The dosification and quantification of basic myelin protein of the central nervous system, rich in citruline in the urine, may be a parameter of progressiveness. CONCLUSION: This methodology (five humours test) may be used to establish an earlier, more certain diagnosis of multiple sclerosis and also monitor its biological activity together with nuclear magnetic resonance with intravenous contrast.
Assuntos
Cognição/fisiologia , Interleucina-2 , Esclerose Múltipla/diagnóstico , Esclerose Múltipla/metabolismo , Receptores de Interleucina-2/análise , Saliva/química , Lágrimas/química , Adulto , Biomarcadores , Potenciais Evocados Visuais/fisiologia , Feminino , Seguimentos , Humanos , Interleucina-2/sangue , Interleucina-2/líquido cefalorraquidiano , Interleucina-2/urina , Masculino , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: As antitumoral immunity requires the generation of local immunity directed against tissue proteins, we attempted to recreate within tumors the same environment found within tissues affected by autoimmune diseases (i.e., prolonged cytokine expression). Vaccinia virus (VV) has not been widely used as a cytokine gene therapy vector because of presumed high immunogenicity that would likely make repeated injections impossible; therefore, we modified it by inserting the cytokine gene into the thymidine kinase region, rendering it replication-restricted. The cytokine chosen was human interleukin-2 (IL-2); a molecule with powerful antitumoral effects. METHODS: Six patients with the treatment-resistant tumor malignant mesothelioma received intratumoral (i.t.) VV-IL-2 therapy for 12 weeks by injection of 10(7) plaque-forming units of VV-IL-2 per dose. Serial tumor biopsies, sputum, urine, and blood samples were tested for VV-IL-2 mRNA expression; VV culture and T-cell infiltrates were evaluated by immunohistochemistry. Patients and contacts of patients were monitored for changes in VV immunoglobulin G (IgG) levels and clinical evidence of VV infection. RESULTS: VV-IL-2 was not excreted and was only cultured in one patient from tumor biopsies. A T-cell infiltrate was detected in 50% of tumor biopsies. VV-IL-2 mRNA expression was highest on days 1-3 postinjection and was detected for up to 3 weeks after each injection even though VV IgG levels rose in all patients. No significant toxicities, infection of patient contacts, or tumor regressions were observed. CONCLUSIONS: I.t. VV-IL-2 administration is safe, is associated with minimal toxicity, and results in i.t. expression of VV-IL-2 for up to 3 weeks postinjection regardless of the level of anti-VV IgG titers generated. This suggests that VV may be a good vector for repeated cytokine gene therapy of solid human cancer.
Assuntos
Terapia Genética/métodos , Vetores Genéticos , Neoplasias Pulmonares/terapia , Mesotelioma/terapia , Transgenes , Vaccinia virus/genética , Adulto , Feminino , Vetores Genéticos/toxicidade , Humanos , Imunoglobulina G/metabolismo , Imuno-Histoquímica , Interleucina-2/biossíntese , Interleucina-2/sangue , Interleucina-2/genética , Interleucina-2/urina , Neoplasias Pulmonares/metabolismo , Masculino , Mesotelioma/metabolismo , Pessoa de Meia-Idade , Projetos Piloto , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Linfócitos T/metabolismo , Timidina Quinase/genética , Fatores de TempoRESUMO
PURPOSE: In patients with superficial bladder cancer treated with a first 6-week instillation course of bacillus Calmette-Guerin (BCG) the induction pattern of urinary interleukin (IL)-2 has been described, and the levels of urinary IL-2 were associated with the clinical response to BCG treatment. We evaluated urinary IL-2 kinetics in patients with recurrent superficial bladder tumor receiving a second or third 6-week BCG instillation course. To our knowledge there have been no studies of prolonged BCG treatment and urinary cytokine responses. MATERIALS AND METHODS: Urinary IL-2 was determined in 12 patients with superficial transitional cell carcinoma of the bladder receiving a complete (6-week) second or third BCG instillation course and in 3 patients receiving 3 BCG instillations during a maintenance schedule at month 3. Urinary IL-2 was determined with an enzyme-linked immunosorbent assay using an oligoclonal system. RESULTS: Of 12 patients 10 had a urinary IL-2 positive response during the subsequent BCG course and at week 1 urinary IL-2 was already increased. Comparing the urinary IL-2 kinetics observed during a second or third with a first course, urinary IL-2 tended to be higher during the first and lower during the last weeks. If the interval between subsequent courses was short (12 months or less) significantly higher urinary IL-2 levels at weeks 1 and 2, and a lower level at week 6 were observed. CONCLUSIONS: During a repeat BCG instillation course urinary IL-2 reached a maximum at an earlier week, especially if the interval between the subsequent courses was short. Since an association between urinary IL-2 levels and response to BCG treatment during an induction course has been observed, these immunological data argue in favor of a limited number of instillations during prolonged BCG therapy which could reduce side effects as well as costs.